Physician profile
Komal Patel
NPI 1023540390
$2,904.58
in general payments reported to CMS, 2019-2025
19 companies · $1,597 in 2025
The $1,597 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,307 · 2025: $1,597.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,885 · Education: $19.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,885.33 |
| Education | $19.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $917.64 | 2024-2025 | Krystexxa, Evenity, Otezla |
| Abbvie INC. | $752.98 | 2024-2025 | |
| Ucb, INC. | $224.63 | 2025 | Bimzelx |
| Novartis Pharmaceuticals Corporation | $136.58 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $130.64 | 2024-2025 | Saphnelo |
| Fresenius Kabi USA, LLC | $117.91 | 2024-2025 | Tyenne, Idacio |
| Glaxosmithkline, LLC. | $93.57 | 2024-2025 | Benlysta |
| Janssen Biotech, INC. | $92.80 | 2024-2025 | Tremfya |
| Pfizer INC. | $73.47 | 2024-2025 | |
| Lilly USA, LLC | $70.54 | 2024-2025 | Taltz |
| Sobi, INC | $61.25 | 2024 | |
| Aurinia Pharma U.S., INC. | $48.92 | 2025 | Lupkynis |
| Mallinckrodt Hospital Products INC. | $40.36 | 2024-2025 | Acthar |
| E.R. Squibb & Sons, L.L.C. | $30.25 | 2024 | Orencia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.15 | 2024 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $27.15 | 2025 | Tymlos |
| Organon LLC | $23.95 | 2025 | Hadlima, Renflexis |
| Alexion Pharmaceuticals, INC. | $18.09 | 2024 | Strensiq |
| Genentech USA, INC. | $16.70 | 2025 | Actemra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Komal Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.